Project ECHO : Viral Hepatitis in sub-Saharan Africa

Extension for Community Health Outcomes



Moving Knowledge Instead of Patients



Project ECHO



Mission

- Founder: Dr Sanjeev Arora, Albuquerque, New Mexico
- To democratize medical knowledge and get best practice care to underserved people all over the world

Goals

- Develop capacity to safely and effectively treat HCV
- Develop a model to treat complex diseases in rural locations and developing countries
- Expanded into 23 countries, managing a range of chronic conditions: viral hepatitis women's health

Touch the lives of 1 Billion people by 2025



ECHO Model of Care



Four basic principles of ECHO model of care:

- Using technology to leverage scarce resources in order to deliver the right knowledge, training and administration, to the right people, at the right time
- 2. Share best practices to reduce disparities of healthcare
- 3. Employ case-based learning to master disease complexities
- 4. Monitor outcomes to ensure ongoing benefit


Arora S, Geppert CM, Kalishmanv S, et al: Acad Med. 2007 Feb;82(2): 154-60





- ECHO links expert specialist teams at an academic 'hub' with primary care clinicians in local communities (the 'spokes')
- Together, they participate in weekly monthly teleECHO clinics, which are like virtual grand rounds, combined with mentoring and patient case presentations
- 15 minute didactic lecture
- The clinics are supported by multipoint telehealth video technology
 ZOOM
- Train doctors, nurses, pharmacists, community healthcare workers and their teams within their own communities
- Establish learning loops

ECHO vs. Telemedicine






```
Learning Loops
```



- Interactive learning environment
- Co-management of cases
- Learning by doing
- Learning from didactics
- Learning from each other
- Collaboration in solving problems













NEJM : 364: 23, June 9-2011, Arora S, Thornton K, Murata G

HCV Case Presentation Form

HEALTI	UNN H SCIENC CENT		+	MINISTRY C HEALTH AN SOCIAL AFI		OUR		Project	0	
	Geo	orgia H	ICV Eliminatio	on Project	Initi	al Pre	sentatio	n Form		
Presentation Da	ate:		Site: Mrcheveli Cli	nic		Cli	nician:			
General Information/Demographics										
Presentation ID			Year o	of Birth:			Gender:	Male	Female	
Ethnicity:	Other:		₹	Rac	e:	Cau		HCV Genotype	:	
Suspected Ro	oute of H	ICV Tra	ansmission (C	heck all th	at a	pply)				
Recipient of c	lotting fact		Blood transfus organ transplant	sion or solid		Needle	estic <mark>k inj</mark> ur	y in healthcare s	setting	
Hemodialysis			Birth to HCV-ii mother	nfected		Sharing		contaminated personal items with HCV- erson		
Sex with HCV-	infected pe	erson	Non-professio	nal tattoo		Cosme	etic transmission (manicure, barber, etc.)			
			user (even once) 12 months? 🔲 Ye			Other i /pe:	invasive m	edical procedur	es	
Other:						unknov	wn			
	noses (C	heck a	all that apply)			r of Diag	masia			
HCV Year of diag	nosis:		Hepatocellu	lar Carcinom	a Yea		gnosis.			
Cirrhosis			Previous HC Year:	V Treatment Previous [)rug f			Responses	₹	
Cirrhosis	mpensatio		Previous HC	V Treatment Previous I atment in we)rug f æks:	Regimen	:	Response:	₹ ₹	
Cirrhosis	ompensatio ariceal blee	ed	Previous HC Year:	V Treatment Previous I atment in we Previous I)rug f eks:)rug f	Regimen	:	Response: Response:		
Cirrhosis Evidence of decco	ompensatio ariceal blee	ed	Previous HC Year: Duration of trea Year:	V Treatment Previous I atment in we Previous I)rug f eks:)rug f	Regimen	:			
Cirrhosis Evidence of decc Ascites Va Hepatic encep Liver Biopsy Known	ompensatio ariceal blee	ed ,	Previous HC Year: Duration of tree Year: Duration of tree Year: Year:	V Treatment Previous I atment in we Previous I atment in we)rug F eeks:)rug F eeks:	Regimen	:: :: Mem			
Cirrhosis Evidence of decc Ascites Vi Hepatic encep Liver Biopsy Known extrahepatic	ompensatio ariceal blee bhalopathy Cryoglo	ed y bulinen	Previous HC Year: Duration of tree Year: Duration of tree Year: Year:	V Treatment Previous I atment in we Previous I atment in we Results:	Drug F eeks: Drug F eeks:	Regimen	:: :: Glomeru	Response: branoproliferatio		
Cirrhosis Cirrhosis Evidence of decc Ascites Vi Hepatic encep Liver Biopsy Known extrahepatic manifestations	ompensatio ariceal blee bhalopathy Cryoglo	ed obulinem ranous N	Previous HC Year: Duration of tree Year: Duration of tree Year: Year:	V Treatment Previous D atment in we Previous D atment in we Results: Vasculitis Lichen Pl Multiple	Drug F eeks: Drug F eeks: anus Myel	Regimen	:: :: Glomeru	Response: branoproliferativ lonephritis iyria Cutanea Ta		
Cirrhosis Cirrhosis Evidence of decc Ascites Vi Hepatic encep Liver Biopsy Known extrahepatic manifestations Asthma	ompensatio rriceal blee ohalopathy Cryoglo Membr B Cell N	ed obulinen ranous N Ion-Hod	Previous HC Year: Duration of tree Year: Duration of tree Year: Hia Hephropathy gkin Lymphoma h Injury	V Treatment Previous D atment in we Previous D atment in we Results: Vasculitis Lichen Pl Multiple	Drug F eeks: Drug F eeks: anus Myel	Regimen Regimen oma	: .: Glomeru Porph	Response: branoproliferatin lonephritis vyria Cutanea Ta		
Cirrhosis Cirrhosis Circhosis Circho	ompensatio rriceal blee ohalopathy Cryoglo Membr B Cell N	ed obulinem ranous N Ion-Hod Brair Hepa	Previous HC Year: Duration of tree Year: Duration of tree Year: Nia lephropathy gkin Lymphoma n Injury stitis B, chronic	V Treatment Previous I atment in we Previous I atment in we Results: Vasculitis Lichen Pl Multiple C Ch	Drug F eeks: Drug F eeks: anus Myel mronid epatit	Regimen Regimen oma c Pain is D	: Glomeru Porph Other	Response: branoproliferatin lonephritis yria Cutanea Ta COPD HIV	rda	
Cirrhosis Cirrhosis Cirrhosis Ascites Va Hepatic encep Liver Biopsy Known extrahepatic manifestations Asthma Diabetes Mellit Hypertension	mpensatio ariceal blee halopathy Cryoglo Membr B Cell N tus	ed obulinem ranous N Ion-Hod Brair Hepa	Previous HC Year: Duration of tree Year: Duration of tree Year: Hia Hephropathy gkin Lymphoma h Injury	V Treatment Previous I atment in we Previous I atment in we Results: Vasculitis Lichen Pl Multiple C Ch Ha y Ref	Drug F eeks: Drug F eeks: anus Myel mronic epatit enal I	Regimen Regimen oma	: Glomeru Porph Other	Response: branoproliferatin lonephritis vyria Cutanea Ta	rda	
Cirrhosis Cirrhosis Circhosis Circho	mpensatio ariceal blee shalopathy Cryoglo Membr B Cell N B Cell N tus	ed obulinem ranous N Non-Hod Brair Hepa Perip	Previous HC Year: Duration of tree Year: Duration of tree Year: Nia lephropathy gkin Lymphoma n Injury stitis B, chronic sheral Neuropath	V Treatment Previous I atment in we Previous I atment in we Results: Vasculitis Lichen Pl Multiple C Ch	Drug F eeks: Drug F eeks: anus Myel mronic epatit enal I	Regimen Regimen oma c Pain is D	: Glomeru Porph Other	Response: branoproliferatin lonephritis yria Cutanea Ta COPD HIV	rda	
Cirrhosis Cirrhosis Evidence of decc Ascites Va Hepatic encep Liver Biopsy Known extrahepatic manifestations Asthma Diabetes Mellit Hypertension Coronary Arter	mpensatio ariceal blee shalopathy Cryoglo Membr B Cell N B Cell N tus	ed obulinen ranous N Ion-Hod Brair Hepa Perip Ty	Previous HC Year: Duration of tree Year: Duration of tree Year: Year: Nia Hephropathy gkin Lymphoma In Injury stitis B, chronic oheral Neuropath pe of disease:	V Treatment Previous I atment in we Previous I atment in we Results: Vasculitis Lichen Pl Multiple C Ch Ha y Ref	Drug F eeks: Drug F eeks: anus Myel mronid epatit enal In ther:	Regimen Regimen oma c Pain is D	: Glomeru Porph Other	Response: branoproliferatin lonephritis yria Cutanea Ta COPD HIV	rda	

Laboratory

Basic Laborato	ries	Date	(DD/MM/YYYY)		
RBC	<i>м/</i> µL		PT	s	
WBC	<i>к/</i> µL		INR		
ANC	<i>κ/</i> μL		Albumin	g/L	mg/d
HGB	g/L	mg/dL	ALT	IU/mL	
нст	%		AST	IU/mL	
Platelets	<i>к/</i> µL		GGT	IU/mL	
ESR	mm/hr		Alk Phos	IU/mL	
Creatinine	µmol/L	mg/dL	T. Bili	µmol/L	mg/d
Glucose	mmol/L	mg/dL	Direct Bili	µmol/L	mg/d
CRP	mg/L		Total Protein	g/L	mg/d

Other Essential Results							
	Date (DD/MM/YYYY)	Result			Date (DD/MM/YYYY)	Result	
Fe		μg/dL		HCV Genotype			
ТІВС		μg/dL		HCV Viral Load			
Ferritin		ng/dL		тѕн			IU/mL
AFP		ng/dL		ANA			
HIV Ab		Reactive Non-reactive		Other:			

Diagnostic Tests

Test	Date (DD/MM/YYYY)	Result			
FIB-4		Final Result:			
		Normal	Ascites	Hepa	tomegaly
Ultrasound		Splenomegaly	Liver mass	Consi	stent with fatty infiltration
		Other:			
Elastography		Score: kPa			
		Normal	Small varices	s	Medium varices
Upper Endoscopy		Large varices	Banding per	formed	
		Other:			
		Normal	Ascites	🗌 Hepa	tomegaly
CT/MRI		Splenomegaly	Liver mass	Consi	stent with fatty infiltration
		Other:			



Arora S, Kalishman S, Thornton K, Dion D et al: Hepatology. 2010 Sept;52(3):1124-33-



Benefits of ECHO



Regular active participation in teleECHO clinics combined with formal teaching allows the rural health care providers to progressively "specialize" and be able to manage their own patients at their place of residence

- Rapidly upscales training of local workforce
- Increases patient access to treatment
- Decreases related morbidity and mortality
- Decreases specialist clinic waiting times

Arora S, Thornton K, et al. Hepatology. 2010 Sept; 52(3):1124-33



SCAN-ECHO



2011: Veterans Health Administration adopted SCAN-ECHO (Specialty Care Access Network - Extension for Community Healthcare Outcomes) : Chronic liver disease

- Assessed efficacy of SCAN-ECHO visit within the context of a regional cohort of 62 237 patients with liver disease from 1/6/2011 to 31/3/2015
- 513 SCAN-ECHO pts compared to 62 234 pts with no ECHO visits
 ECHO patients were younger, rural with HCV, HBV or cirrhosis
- Matched patients with SCAN-ECHO program consultation
 - 46% less likely to die during follow-up period, HR 0.54; 95% CI 0.36-0.81; P = 0.003) compared to those with no ECHO visits
 - More likely to undergo surveillance for oesophageal varices and HCC
 - >40% patients had hepatitis C
 - Similar survival compared to traditional in-person visits

Su et al; Hepatology 2018;00:1-8







Implementation of supranational model in four pilot countries : South Africa, Nigeria, Ghana and Ethiopia

- Development of hub and spoke services to diagnose and treat a greater number of HBV and HCV infected individuals than are currently treated
- Provides a platform in SSA for:
 - Best-practice care for patients with complex health conditions
 - Outcomes research

By "Democratizing" knowledge and practice, we can exponentially increase local capacity to diagnose and treat the disease, in order to meet the 2030 WHO elimination targets for chronic viral hepatitis

Can be expanded to management of other chronic conditions



ECHO PROGRAM : SSA



HUBS

South Africa

- Liver clinic, Groote Schuur Hospital
- University of Witwatersrand & Donald Gordon Medical Centre

SPOKES

Liver Clinic, GSH: Start with centres already part of our referral base

• Worcester, Paarl, George, Mthatha, Port Elizabeth, East London

4 Internationally linked spoke centres

- Nigeria: The University of Lagos, Lagos (Prof Funmi Lesi)
- Ghana: Kwame Nkrumah University of Science and Technology, Kumasi (Prof Mary Afihene)
- Ethiopia: Adis Ababa University Medical School, (Prof Abate Shewaye)
- London: UCL Institute of Liver and Digestive Disease and Kings College Hospital (Prof G Dusheiko); support and guidance



The SSA ECHO Viral Hepatitis program will support:

- A series of didactic lectures and case discussions
- Clinically approved cost effective prescribing of drug treatments in accordance with local procurement policy
- Spokes at the University of Lagos, Kumasi Hospital, Ghana and Adis Ababa developing into Hubs with their own spokes
- Progressively increase the number of spokes in SA





Project ECHO programs

- Highly-regulated system of anonymizing and encrypting data and personal information to ensure data protection, confidentiality and security
- Expanded to treat other chronic conditions using the same infrastructure
 - Diabetes Mellitus and hypertension
 - Rheumatology
 - Palliative care
 - Oncology
- Already HIV ECHO programs in Namibia and Kenya
- Planned Oncology program: Kimberley Hospital, SA

Successful Expansion into Multiple Diseases

	Mon	Tue	Wed	Thurs	Fri
8-10	<u>Hepatitis C</u> • Arora	<u>Diabetes &</u> Endocrinology		<u>Geriatrics/</u> Dementia	<u>Palliative</u> <u>Care</u>
a.m.	• Thornton	Bouchonville		• Herman	• Neale
10-12 a.m.	<u>Rheumatology</u> • Bankhurst	<u>Chronic Pain</u> • Katzman	Integrated Addictions & Psychiatry • Komaromy		<u>Complex</u> <u>Care</u> • Neale • Komaromy
2-4 p.m.	<u>HIV</u> • landiorio • Thornton		Prison Peer Educator Training • Thornton	<u>Women's</u> <u>Health &</u> <u>Genomics</u> • Curet	Kontaronny




Copyright 2013 Project ECHO®



Force Multiplier

Use Existing Community Clinicians



Project ECHO: Viral Hepatitis in sub-Saharan Africa

Extension for Community Health Outcomes



Moving Knowledge Instead of Patients

Start-up funding from Gilead Grants Program (G Dusheiko)

• First ECHO clinic February 2019





Videoconferencing Hardware : HUBS

- Microphones system: 1500 USD x 13.5 = R 20 250
- Speakers system: 1000 USD x 13.5 = R 13 500
- Webcam: 1500 USD x 13.5 = R 20 250
- 2 x high definition displays/monitors: 4000 USD = R 54 000
- Computer: 1500 USD x 13.5 = R20 250
- Network: WIFI or LAN
- Videoconferencing Software: ZOOM
 - Provided free from ECHO

Total : R 128 250

ECHO Project : Infrastructure

Videoconferencing Hardware : SPOKES

- Microphones system: 500 USD x 13.5 = R 6 750
- Speakers system: 1000 USD x 13.5 = R 13 500
- Webcam: 1500 USD x 13.5 = R 20 250
- 1 x high definition displays/monitors: 2000 USD = R 27 000
- Computer: 1500 USD x 13.5 = R20 250
- Network: WIFI or LAN
- Videoconferencing Software: ZOOM
 - Provided free from ECHO

Total : R63 450



ECHO PROGRAM : SSA



The team structures would include:

Hub medical director

Recruitment of spokes and management, curriculum development

- Clinicians: Specialists (Hubs), primary healthcare clinicians (spokes)
- Clinical co-ordinators
 - Manages day-to-day supervision of ECHO clinics and data collection
- IT co-ordinators
- Pharmacists
- Social worker
- Nursing sisters
- Community health workers